Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes

Sponsor
International Institute of Molecular and Cell Biology in Warsaw
Study ID
NCT07604883
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Atypical Parkinsonism
  • Dementia With Lewy Bodies (DLB)
  • Multiple System Atrophy
  • PARKINSON DISEASE (Disorder)
  • Progressive Supranuclear Palsy (PSP)

Eligibility Criteria

Sex
ALL
Age
40 Years - 80 Years
Healthy Volunteers
Accepted

Study Details

This prospective observational study aims to identify and preliminarily validate molecular biomarkers, including microRNAs and metabolites, for the early differentiation of Parkinson's disease (PD) from atypical parkinsonian syndromes (APS). The study will enroll up to 100 patients with PD, 50 patients with suspected APS, and 50 healthy controls. Participants will undergo clinical assessments and provide blood, urine, and stool samples at baseline and after 12-18 months of follow-up. Molecular analyses, including microRNA profiling, metabolomics, RNA sequencing (RNA-seq), and microbiome analysis, will be performed to identify disease-specific diagnostic signatures. The primary objective is to detect differences in molecular profiles among patients with PD, patients with APS, and healthy controls. Secondary objectives include evaluating the diagnostic accuracy of biomarker panels and assessing longitudinal changes in these biomarkers over time. Although participants will not receive direct therapeutic benefits, the study may contribute to the development of non-invasive tools for the early diagnosis and improved differentiation of parkinsonian disorders.

Key Dates

First listed
May 22, 2026
Start date
Jun 4, 2026
Status verified
May 2026
Primary completion
Jan 4, 2029
Completion
Jun 4, 2029

Study Design

Enrollment
200 participants (estimated)

Primary Outcome Measure

Differential expression of selected microRNAs [ Time Frame: 18 months ]

Central Contacts

Related Studies